Increased plasma concentration of natriuretic peptides by selective β1-blocker bisoprolol

Journal of Cardiovascular Pharmacology

Volumn 42, Issue 4, 2003, Pages 462-468

  Van den Meiracker, Anton H ^a   Lameris, Thomas W ^a   Van de Ven, Louis L M ^a   Boomsma, Frans ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

adrenoceptor blockade; Ambulatory blood pressure; Atrial natriuretic peptide; B type natriuretic peptide; Bisoprolol; Losartan; N terminal natriuretic peptide

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; LOSARTAN; N TERMINAL NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE CLEARANCE RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG SELECTIVITY; FEMALE; HEART VENTRICLE; HORMONE BLOOD LEVEL; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DENSITY;

ADOLESCENT; ADULT; AGED; ALDOSTERONE; BISOPROLOL; BLOOD PRESSURE; CATECHOLAMINES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; LOSARTAN; MALE; MIDDLE AGED; NATRIURETIC PEPTIDES; NETHERLANDS; RENIN;

EID: 0141753985     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200310000-00002     Document Type: Article

References (23)

1. Nakaoka H, Kitahara Y, Amano M, et al. Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension. Hypertension. 1987;10:221-225.
2. Hana J, Nagata S, Takenaka T, et al. Atrial natriuretic peptide and antihypertensive action due to beta-blockade in essential hypertensive patients. Angiology. 1995;46:511-516.
3. Papadopoulos CL, Kokka B, Kotridis P, et al. Effect of the beta 1-blocker/beta 2-agonist celiprolol on atrial natriuretic peptide plasma levels in hypertensive patients. Cardiovasc Drug Ther. 1998;12:345-346.
4. Yoshimoto T, Naruse M, Tanabe A, et al. Potentiation of natriuretic peptide action by the beta-adrenoceptor blocker carvedilol in hypertensive rats: a new antihypertensive mechanism. Endocrinology. 1998;139:81-88.
5. Petrie JC, O'Brien ET, Littler WA, et al. Recommendations on blood pressure measurement. Br Med J. 1986;93:611-615.
6. Boomsma F, Deinum J, van den Meiracker AH. Relationship between natriuretic peptide concentrations in plasma and posture during sampling. Clin Chem. 2001;47:963-965.
7. Van den Hoorn FAJ, Boomsma F, Man in 't Veld AJ, et al. Determination of catecholamines in human plasma by high performance liquid chromatography: Comparison between a new method with fluorescence detection and an established method with electrochemical detection. J Chromatogr. 1989;487:17-27.
8. Luchner A, Burnett JC, Jougasaki M, et al. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol. 1998;32:1839-1844.
9. Wong NLM, Wong EFC, Au GH, et al. Effect of alpha and beta-adrenergic stimulation on atrial natriuretic peptide release in vitro. Am J Physiol. 1988;255:E260-E264.
10. Schiebinger RJ, Baker MZ, Linden J. Effect of adrenergic and muscarinic cholinergic agonists on atrial natriuretic peptide secretion by isolated rat atria. J Clin Invest. 1987;80:1678-1691.
11. Christensen G, Ilebekk A, Kiil F. Release of atrial natriuretic factor during infusion of isoproterenol and angiotensin II. Am J Physiol. 1989;257: R896-R900.
12. Christensen G, Aksnes G, Ilebekk A, et al. Release of atrial natriuretic factor during selective cardiac alpha- and beta-adrenergic stimulation, intracoronary Ca infusion, and aortic constriction in pigs. Circ Res. 1991;68:638-644.
13. 1-adrenergic stimulation of isolated rat atria results in discoordinate increases in natriuretic peptide secretion and gene expression and enhances Egr-1 and c-Myc expression. Endocrinology. 1996;137:137-143.
14. Hanford DS, Thureauf DJ, Murray SF, et al. Brain natriuretic peptide is induced by alpha1-adrenergic agonists as a primary response gene in cultured rat cardiac myocytes. J Biochem Chem. 1994;269:2627-2633.
15. Nakagawa O, Itoh H, Harada M, et al. Gene regulation of brain natriuretic peptide in cardiocyte hypertrophy by alpha1-adrenergic stimulation. Clin Exp Pharm Phys. 1995;(Suppl 1)S183-S185.
16. Suzuki E, Hirata Y, Kohmoto O, et al. Cellular mechanisms for synthesis and secretion of atrial natriuretic peptide and brain natriuretic peptide in cultured rat atrial cells. Circ Res. 1992;71:1039-1048.
17. Wiese S, Breyer T, Dragu A, et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: Influence of angiotensin II and diastolic fiber length. Circulation. 2000;19:3074-3079.
18. Janssen WMT, de Zeeuw D, van der Hem GK, et al. Antihypertensive effect of 5-day infusion of atrial natriuretic factor in humans. Hypertension. 1989;13:640-646.
19. Pidgeon GB, Richards AM, Nicholls MG, et al. Different metabolism and bioactivity of atrial and brain natriuretic peptides in essential hypertension. Hypertension. 1996;27:906-913.
20. Boomsma F, van den Meiracker AH. Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res. 2001;51:442-449.
21. Dries DL, Stevenson LW. Brain natriuretic peptide as a bridge to therapy for heart failure (Commentary). Lancet. 2000;355:1112-1113.
22. Teisman ACH, van Veldhuizen DJ, Boomsma F, et al. Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones. Int J Cardiol. 2000;73:7-12.
23. Goldstein S, Kennedy HL, Hall C, et al. Metroprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction. Am Heart J. 1999;138:1158-1165.